

DETROIT CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
1	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	Systemic Lupus Erythematosus Cutaneous Lupus	Drug: Tofacitinib	University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT05048238
2	A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy	Subacute Cutaneous Lupus Erythematosus Chronic Cutaneous Lupus Erythematosus	Drug: BIIB059 (litifilimab) Drug: Placebo	Revival Research Institute, LLC, Troy, Michigan, United States David Fivenson, MD, Dermatology, PLLC, Ann Arbor, Michigan, United States AA MRC LLC Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States	https://ClinicalTrials.gov/show/NCT05531565
3	A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Deucravacitinib Other: Placebo	University of Michigan, Ann Arbor, Michigan, United States AA Medical Research Center-Grand Blanc, Grand Blanc, Michigan, United States University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT05620407
4	A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care	Lupus Erythematosus, Systemic	Drug: BIIB059 (litifilimab) Drug: Placebo	Research Site, Grand Blanc, Michigan, United States Research Site, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT04895241
5	A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: DZP Other: Placebo	SI0043 50219, Detroit, Michigan, United States SI0043 50333, Grand Blanc, Michigan, United States	https://ClinicalTrials.gov/show/NCT04294667

DETROIT CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
6	A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus (SLE)	Drug: BIIB059 (litifilimab) Drug: Placebo	Research Site, Grand Blanc, Michigan, United States Research Site, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT05352919
7	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Nephrology Research of Michigan, Saint Clair Shores, Michigan, United States Metro Health Medical Center, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT04221477
8	Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus	Active Systemic Lupus Erythematosus	Drug: Efavaleukin Alfa Drug: Placebo Other: Standard of Care	Michigan Rheumatology Group, PC - Grand Blanc Office, Grand Blanc, Michigan, United States Arthritis and Rheumatology of Michigan, Lansing, Michigan, United States	https://ClinicalTrials.gov/show/NCT04680637
9	The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)	Systemic Lupus Erythematosus	Drug: Enpatoran low dose Drug: Enpatoran medium dose Drug: Enpatoran high dose Drug: Placebo	AA MRC LLC Ahmed Arif Medical Research Center, Grand Blanc, Michigan, United States University of Toledo - PARENT, Toledo, Ohio, United States	https://ClinicalTrials.gov/show/NCT05162586
10	Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Lupus Nephritis	Drug: ianalumab s.c. q4w Drug: ianalumab s.c. q12w Drug: placebo s.c.	Novartis Investigative Site, Detroit, Michigan, United States Novartis Investigative Site, Lawrenceville, Georgia, United States Novartis Investigative Site, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT05126277
11	Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis	Lupus Nephritis	Drug: Anifrolumab Drug: Placebo	Research Site, Middleburg Heights, Ohio, United States	https://ClinicalTrials.gov/show/NCT05138133

DETROIT CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
12	Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Medi-546 Drug: Placebo	Research Site, Flint, Michigan, United States	https://ClinicalTrials.gov/show/NCT04877691
13	Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Discoid Lupus Erythematosus	Drug: Placebo/Daxdilimab Drug: Daxdilimab	Michigan Dermatology Institute, Waterford, Michigan, United States	https://ClinicalTrials.gov/show/NCT05591222
14	A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Other: Placebo Drug: Nipocalimab Drug: Standard-of-care treatment	Paramount Medical Research, Middleburg Heights, Ohio, United States	https://ClinicalTrials.gov/show/NCT04882878
15	Atacicept in Subjects With Active Lupus Nephritis (COMPASS)	Lupus Nephritis (LN)	Drug: Atacicept Drug: Placebo	Vera Site # 0148, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT05609812
16	A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: Deucravacitinib Other: Placebo	Henry Ford Hospital, Detroit, Michigan, United States	https://ClinicalTrials.gov/show/NCT05617677
17	A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: LY3361237 Drug: Placebo	Paramount Medical Research, Middleburg Heights, Ohio, United States	https://ClinicalTrials.gov/show/NCT05123586
18	ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: ALPN-101 Drug: Placebo	Investigational Site (138), Grand Blanc, Michigan, United States	https://ClinicalTrials.gov/show/NCT04835441
19	A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Telitacicept Drug: Placebo	Grand Blanc Site, Grand Blanc, Michigan, United States	https://ClinicalTrials.gov/show/NCT05306574

DETROIT CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
20	Ataccept in Subjects With Active Lupus Nephritis (COMPASS)	Lupus Nephritis (LN)	Drug: Ataccept Drug: Placebo	Vera Site # 0148, Cleveland, Ohio, United States	https://ClinicalTrials.gov/show/NCT05609812
21	A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: Afimetoran Other: Placebo	Paramount Medical Research & Consulting, Llc, Middleburg Heights, Ohio, United States	https://ClinicalTrials.gov/show/NCT04895696
22	A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Obinutuzumab Drug: Placebo Drug: Acetaminophen/Paracetamol Drug: Diphenhydramine hydrochloride Drug: Methylprednisolone	Paramount Medical Research & Consulting, LLC, Middleburg Heights, Ohio, United States	https://ClinicalTrials.gov/show/NCT04963296
23	A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)	Lupus Erythematosus, DLE/SCLE	Drug: Deucravacitinib Drug: Placebo	University Of Michigan, Ann Arbor, Michigan, United States	https://ClinicalTrials.gov/show/NCT04857034
24	PRV-3279-2a Trial in Systemic Lupus	Efficacy and Safety	Biological: PRV-3279 Other: Placebo	Clinical Site, Toledo, Ohio, United States	https://ClinicalTrials.gov/show/NCT05087628
25	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	Systemic Lupus Erythematosus (SLE) and others	Biological: Moderna mRNA-1273 Biological: BNT162b2 Biological: Ad26.COV2.S Drug: Continue IS (MMF or MPA)	University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States Cleveland Clinic, Cleveland, Ohio, U.S.A.	https://ClinicalTrials.gov/show/NCT05000216
26	Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Advanced Malignant Solid Neoplasm Autoimmune Disease	Procedure: Biospecimen Collection Biological: Nivolumab	Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States	https://ClinicalTrials.gov/show/NCT03816345

If you think you may be a candidate to participate in a clinical trial, then consider taking the information back to your loved ones and personal physician and have a very serious conversation with them. Making the choice to participate in a clinical trial is not only a major decision, but a very personal one that should be based on discussions with your family members and treating physicians familiar with your history. We cannot emphasize this strongly enough.